Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Advanced Malignant Solid Neoplasm: early-phase trial registry
27 of 109 indexed Advanced Malignant Solid Neoplasm trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #117 of 28,707 conditions by registered trial count.
109 US clinical trials · 27 currently recruiting · #117 of 28,707 conditions by registered trial count
Advanced Malignant Solid Neoplasm: 109 US clinical trials tracked, 27 recruiting.
Advanced Malignant Solid Neoplasm is the subject of 109 registered US clinical trials on ClinicalTrials.gov, 27 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 99 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 67 of these trials.
Enrollment posture brief
Registry condition advanced-malignant-solid-neoplasm
OPEN 27 | RECR 25% | LATE 1 | EARLY 99 | RANK #117 | SPON 67
Volume-matched condition peers
Nearest open-share peer: Abdominal Cancer (25% recruiting · 8 trials)
Advanced Malignant Solid Neoplasm lists 27 open slots (25% of 109 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Advanced Malignant Solid Neoplasm on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Advanced Malignant Solid Neoplasm is recruiting below its size-band peers.
27 of 109 indexed trials (24.8%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Advanced Malignant Solid Neoplasm research.
National Cancer Institute (NCI) accounts for 67 of 109 trials (61.5%). 17 distinct sponsors appear on at least one study for this condition label.
-
Most Advanced Malignant Solid Neoplasm trials plan to enrol fewer than 100 people.
Median target enrolment is 45 among the 109 trials that report a genuine target (sentinel values excluded). 86 of those (78.9%) plan for fewer than 100 participants.
-
Advanced Malignant Solid Neoplasm research is mostly interventional.
106 interventional and 3 observational studies make up this index (97.2% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
109 total, page 1 of 3
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
National Cancer Institute (NCI)
NCT05564377
Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)
National Cancer Institute (NCI)
NCT06311214
Olanzapine Versus Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients
Alliance for Clinical Trials in Oncology
NCT04939090
Impact of Project ECHO on Improving the Quality of Palliative Care in Patients With Advanced Cancer and Their Caregivers in Underserved Areas of Kenya, Nigeria, Ghana, South Africa, India, and Ethiopia
M.D. Anderson Cancer Center
NCT04984551
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
RasCal Therapeutics
NCT04678648
Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial
M.D. Anderson Cancer Center
NCT04693468
Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial)
National Cancer Institute (NCI)
NCT05638295
The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With Advanced Solid Tumor Cancers Being Treated With Standard of Care Checkpoint Inhibitors
University of California, Davis
NCT05967533
Studying TAK-243 in Patients With Advanced Cancer
National Cancer Institute (NCI)
NCT06223542
CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors
Northwestern University
NCT05733000
Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial
National Cancer Institute (NCI)
NCT05327010
A Cancer Vaccine (Labvax 3(22)-23) and GM-CSF Alone or in Combination With Pembrolizumab for the Treatment of Advanced Stage Adenocarcinoma
Tianhong Li
NCT05101356
Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer
OHSU Knight Cancer Institute
NCT05705492
Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid Tumors
National Cancer Institute (NCI)
NCT05687136
Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness
National Cancer Institute (NCI)
NCT05691491
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
M.D. Anderson Cancer Center
NCT05039801
TR-002 for the Treatment of Advanced, Unresectable or Metastatic Solid Tumors and Unresectable or Metastatic, Refractory Pancreatic Adenocarcinoma
University of California, Davis
NCT07189195
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
National Cancer Institute (NCI)
NCT04704661
Educational Tools for the Improvement of Early Advance Care Planning in Adolescents and Young Adults With Advanced Solid Tumors and High-Grade Brain Tumors
Mayo Clinic
NCT07174661
Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors
National Cancer Institute (NCI)
NCT05053971
Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer
Roswell Park Cancer Institute
NCT04511039
Phase I/II Randomized Study of NBTXR3 Activated by Abscopal or RadScopal Radiation in Combination With Immunotherapy (Anti-PD-1/L-1) for Patients With Advanced Solid Malignancies
M.D. Anderson Cancer Center
NCT05039632
Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients With Advanced Cancer, CIRES Trial
Yuanquan Yang
NCT06470971
Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors
OHSU Knight Cancer Institute
NCT06320405
AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease
University of Southern California
NCT05791448
Testing How the Body Responds to the Drug CBX-12 in Patients With Advanced Solid Cancers
National Cancer Institute (NCI)
NCT05691517
Fasting Mimicking Diet for Reducing Immune Related Adverse Events for Cancer Patients on Immune Checkpoint Inhibitors, FMD-ICI Trial
Mayo Clinic
NCT06438588
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
NCT02465060
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
National Cancer Institute (NCI)
NCT03155620
Does the Use of a Genomic Tumor Board Increase the Number of Patients Who Receive Genome-Informed Treatment
SWOG Cancer Research Network
NCT05455606
Learning Collaborative Versus Technical Assistance in Delivering a Palliative Care Program to Patients With Advanced Cancer and Their Caregivers
University of Rochester NCORP Research Base
NCT04062552
Frequency of Cachexia in Ambulatory Cancer Patients and Psychological Burden in Patients and Their Primary Caregivers
M.D. Anderson Cancer Center
NCT04090619
Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies
M.D. Anderson Cancer Center
NCT03217747
Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic
M.D. Anderson Cancer Center
NCT02721732
Anamorelin Hydrochloride, Physical Activity, and Nutritional Counseling in Decreasing Cancer-Related Fatigue in Patients With Incurable Metastatic or Recurrent Solid Tumors
M.D. Anderson Cancer Center
NCT03035409
A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors
National Cancer Institute (NCI)
NCT02498613
Veliparib and Dinaciclib in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
NCT01434316
Technology-Enhanced Palliative Care for Advanced Cancer Patients
M.D. Anderson Cancer Center
NCT04989556
Patient Considerations of Social Media Account Management After Death
M.D. Anderson Cancer Center
NCT05035667
Open Labeled Placebo in Reducing Cancer Related Fatigue in Patients With Advanced Cancer
M.D. Anderson Cancer Center
NCT03927885
Physical Activity With or Without Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Locally Advanced, Metastatic, or Recurrent Cancer
M.D. Anderson Cancer Center
NCT03583255
Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation
M.D. Anderson Cancer Center
NCT03065387
Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations
National Cancer Institute (NCI)
NCT03212274
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer
National Cancer Institute (NCI)
NCT04491942
Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)
National Cancer Institute (NCI)
NCT04439175
Mindfulness-Based Intervention for Latino Cancer Patients and Their Caregivers
M.D. Anderson Cancer Center
NCT04870788
Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer
National Cancer Institute (NCI)
NCT01480154
Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer
National Cancer Institute (NCI)
NCT04294628
Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy
Jonsson Comprehensive Cancer Center
NCT03830918
Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN
National Cancer Institute (NCI)
NCT04317105
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 44 |
| Phase 2 | 55 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Advanced Malignant Solid Neoplasm records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Advanced Malignant Solid Neoplasm trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Advanced Malignant Solid Neoplasm page
109 registered trials, 27 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 27 Advanced Malignant Solid Neoplasm trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Advanced Malignant Solid Neoplasm trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Advanced Malignant Solid Neoplasm condition card totals 109 registered trials; most-linked intervention Biospecimen Collection; top US site state Pennsylvania. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.